CLINICAL TRIALS PROFILE FOR SINGULAIR
✉ Email this page to a colleague
All Clinical Trials for Singulair
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00115297 ↗ | Montelukast for Early Life Wheezing | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2/Phase 3 | 2004-09-01 | This study will determine the effects of montelukast on the duration of wheezing in children 12 months to 3 years of age who visit a physician for care of a wheezing illness. Only patients from the Ankara area of Hacettepe University Medical Center in Turkey will be included in this study. |
| NCT00115297 ↗ | Montelukast for Early Life Wheezing | Completed | University of Massachusetts, Worcester | Phase 2/Phase 3 | 2004-09-01 | This study will determine the effects of montelukast on the duration of wheezing in children 12 months to 3 years of age who visit a physician for care of a wheezing illness. Only patients from the Ankara area of Hacettepe University Medical Center in Turkey will be included in this study. |
| NCT00119015 ↗ | The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis | Terminated | Merck Sharp & Dohme Corp. | Phase 4 | 2005-07-01 | Some people with nasal allergy symptoms continue to have symptoms even after treatment with a nasal steroid spray. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the active medication but does not contain the drug). |
| NCT00119015 ↗ | The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis | Terminated | University of Chicago | Phase 4 | 2005-07-01 | Some people with nasal allergy symptoms continue to have symptoms even after treatment with a nasal steroid spray. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the active medication but does not contain the drug). |
| NCT00127647 ↗ | An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-11-01 | The purpose of this trial is to evaluate the efficacy and safety of an investigational drug in adult patients with allergic rhinitis. |
| NCT00162864 ↗ | A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 1999-12-01 | This randomized, double-blind, placebo-controlled trial assessed the efficacy of montelukast in the treatment of adults ≥50 years of age with persistent asthma and/or COPD. Primary outcomes included forced expiratory volume in one-second (FEV1) and daytime asthma symptoms scores. Nocturnal symptoms, asthma control, health-related quality of life, peak flow measurements, and health care utilization were also assessed as secondary outcomes. Participants were recruited from the Kaiser Permanente Northwest member population. One hundred forty-nine subjects were randomized to treatment with montelukast (10 mg per day) or placebo, and were followed for a six-week period. No differences in lung function measures, health-related quality of life, health care utilization, and asthma symptom scores were observed; however, the montelukast group had slightly improved asthma control scores compared to the placebo group. |
| NCT00162864 ↗ | A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease | Completed | Kaiser Permanente | Phase 3 | 1999-12-01 | This randomized, double-blind, placebo-controlled trial assessed the efficacy of montelukast in the treatment of adults ≥50 years of age with persistent asthma and/or COPD. Primary outcomes included forced expiratory volume in one-second (FEV1) and daytime asthma symptoms scores. Nocturnal symptoms, asthma control, health-related quality of life, peak flow measurements, and health care utilization were also assessed as secondary outcomes. Participants were recruited from the Kaiser Permanente Northwest member population. One hundred forty-nine subjects were randomized to treatment with montelukast (10 mg per day) or placebo, and were followed for a six-week period. No differences in lung function measures, health-related quality of life, health care utilization, and asthma symptom scores were observed; however, the montelukast group had slightly improved asthma control scores compared to the placebo group. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Singulair
Condition Name
Clinical Trial Locations for Singulair
Trials by Country
Clinical Trial Progress for Singulair
Clinical Trial Phase
Clinical Trial Sponsors for Singulair
Sponsor Name
